June 7, 2024 – HORIBA introduced that its high-throughput hematology analyzer Yumizen H2500 has obtained 510(ok) clearance from the U.S. Meals and Drug Administration (FDA) and is now accessible on the market in the US. Designed for medium to excessive quantity laboratories, the Yumizen H2500 processes 120 samples per hour and presents a number of take a look at parameters that may alert essential pathologies. From a single blood pattern, the HORIBA Yumizen H2500 hematology analyzer experiences full blood depend (CBC) and WBC differential (DIFF) outcomes, plus a complete immaturity measurement for leukocyte depend in a single run, perfect for oncological pathologies.

Different choices embrace the variety of nucleated crimson blood cells, which is interference-free for platelet aggregates, three new fluorescence-free parameters for big platelets, and the six managed parameters for physique fluid evaluation. The Yumizen H2500 can be utilized standalone or as a totally automated modular resolution HELO 2.0 by combining with a monitoring system.

When put in as HELO 2.0, as much as six Yumizen H2500 analyzers and 6 slide preparation techniques may be put in on a single monitor, with greater than 200 preloaded traces accessible within the hematology skilled validation station. Yumizen H2500 is designed to be eco-friendly and cut back environmental influence. It obtained the 2023 Medical Gadget Community Excellence Award within the Atmosphere class.

This was acknowledged by, for instance, the Yumizen H2500, which requires solely six reagents, in comparison with an business customary of 8-15. Not solely decreasing reagent use, but in addition waste, toxicity and packaging.

The newest analysis outcomes supporting the efficiency of the FDA-approved Yumizen H2500 shall be offered on the 2024 ADLM Convention in Chicago, July 27 to August 1.

For Yumizen H2500 product info, please go to the corporate web site: https://horiba.hyperlink/ih1